Mcyrmeaning

Another symptom of a bad camshaft sensor is poor fuel mileage. This issue likely occurs when a camshaft sensor tells a car’s computer it needs more fuel than it actually does. When this happens, drivers pump unnecessary fuel into their rides simply because of a bad reading. These frequent trips to the gas station can add up quickly. Trucking companies who manage large fleets don’t want to spend more money than necessary, as running a business is expensive enough already. That’s why drivers should inform their supervisors of any engine troubles the minute they notice them. The quicker the problems get resolved, the better the situation will be for everyone.

Secure .gov websites use HTTPS A lock ( Lock Locked padlock icon ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

As previously discussed, the camshaft and crankshaft sensors provide power to the transmission. So, people will likely notice transmission troubles if either of these parts is damaged. One issue that folks may experience includes difficulty switching gears while driving. People may also notice that their transmission appears to be stuck in one gear until they turn the engine on and off a few times. Transmission problems are costly and incredibly dangerous. Anyone who notices transmission trouble while they’re on the road should visit a mechanic immediately.

Mcyrsummer camp

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

No one should have to put considerable weight on the gas pedal to get a car to move. Drivers who recognize they can’t get their car to go over 40mph should promptly call a repair specialist. Diesel engines don’t have spark plugs. Thus, they rely on the air-fuel mixture that’s created in the engine to get things up and running. If the sensor that opens the valves is broken, the engine will not have the appropriate mixture it needs to drive smoothly. So, drivers will have to use much more effort to get the same amount of power as they would when the component functions as it should. Jerking motions are also associated with poor acceleration. Folks whose cars are always stopping and going on the road should speak to a repair specialist as soon as possible. These professionals will figure out if a sensor is damaged and come up with solutions to resolve the problem.

Official websites use .gov A .gov website belongs to an official government organization in the United States.

There’s no feeling akin to the dread of seeing a check engine light come on. Of course, this light can become illuminated for a variety of different reasons. One of those reasons could be a defective camshaft sensor. Some people are notorious for ignoring their check engine lights. These folks hope the issue will resolve itself after a few days. This isn’t a smart move that other people should follow. In fact, everyone should take their car or truck to a repair specialist as soon as they see the light. If the camshaft sensor is actually malfunctioning, it’s smarter to get the problem fixed quickly before it’s too late.

We further assessed the predictive value of baseline variables for the achievement of MCyR using a logistic regression model. Baseline variables with P-values⩽0.35 in the univariate analysis were selected for inclusion and variables that may cause multilinearity were removed from the logistic model. The final model included five baseline variables (baseline CHR, baseline HU use, MCyR to the most recent TKI, number of prior approved TKIs and MCyR to previous imatinib), with an acceptable goodness-of-fit (Akaike information criterion score of 68.22) and an R-squared value (R2)=0.1940 for the logistic analysis. The achievement of MCyR with the most recent TKI (odds ratio 4.951 (95% CI 1.234–19.866); P=0.0240) was the only statistically significant predictor for achieving MCyR on omacetaxine of the five factors remaining in the final model (Table 1).

A camshaft sensor is a vital component of a diesel engine. The part determines when valves open and shut so that an air-fuel mixture can pass through them. This air-fuel mixture is transported to the crankshaft, where it’s converted into energy that starts the transmission. Since it performs such an essential job, drivers are in for a major headache if the sensor is ever damaged. Thus, everyone should know the symptoms of a bad camshaft sensor, so they can address the issue right away. Neglecting these problems may cause an engine to fail entirely.

ATL Diesel operates independently and is neither sponsored by nor affiliated with any OEM manufacturer. The parts featured on this website are aftermarket replacements and should not be misinterpreted as products or trademarks of any OEM company. Any reference to specific manufacturers' models is intended solely to identify compatible aftermarket parts. These components are not original equipment but are designed as replacement aftermarket parts and accessories.

Engine stalling is incredibly dangerous. The term refers to a vehicle slowing or stopping while a person is driving. Unfortunately, the problem is more likely to occur when a camshaft sensor is damaged. A camshaft sensor should tell the car’s computer when the air-fuel mixture needed to keep the engine running is just right. This doesn’t happen when the sensor is broken. Instead, when the engine stalls, the air-fuel mixture is extremely low on fuel. The air-fuel mixture isn’t powerful enough to keep the engine running. Any driver who experiences engine stalling should call for help right away. An automotive technician will address the problems with the sensor so that it can get the correct reading.

MCyRCML

These results indicate that achievement or maintenance of CHR through 3 months and MCyR at 12 months with omacetaxine may be associated with favorable survival (⩾30 months) in CML-CP patients previously treated with two or more TKIs. Meaningful response milestones may take longer to achieve in heavily pretreated patients receiving omacetaxine and may differ from those used for TKIs. Nevertheless, achievement and/or maintenance of CHR at 3 months with omacetaxine may be a clinically meaningful indicator of benefit to omacetaxine.

Although many chronic myeloid leukemia (CML) patients initially do well with tyrosine kinase inhibitors (TKIs), some patients develop resistance or intolerance to multiple TKIs and need further therapy. Omacetaxine mepesuccinate (omacetaxine), a protein synthesis inhibitor, represents a new class of treatment that can produce major cytogenetic response (MCyR) in patients with CML who have developed resistance or intolerance to TKIs. The US Food and Drug Administration approved subcutaneous omacetaxine for treatment of CML in chronic-phase (CP) and accelerated-phase patients, with resistance or intolerance to two or more TKIs based on efficacy analysis of a subset of patients from two phase 2, open-label, international, multicenter studies.1, 2 Among the 76 evaluable patients with CML-CP in the efficacy analysis, MCyR was reported in 14 patients (18.4%), including confirmed complete cytogenetic response (CCyR) in six patients (7.9%), with a median MCyR duration of 12.5 months.2, 3 Median progression-free survival (PFS) and overall survival (OS) in CML-CP patients were 9.6 months (95% confidence interval (CI) 6.8–11.3 months) and 40.3 months (95% CI 23.8 months–not reached), respectively.

Baseline variables with P-value ⩽0.1 and number of prior approved TKIs were included in the logistic regression model. CHR to the most recent TKI was excluded because of collinearity in logisitic regression analysis.

We thank the investigators in the Omacetaxine-202 and -203 Study Groups, the patients and their families, as well as the clinical study staff for their dedication and support. We dedicate this report in the memory of Dr Meir Wetzler, whose passion and contributions for improving the care and treatment of patients with leukemia in addition to advancing the science of hematologic malignancies have been invaluable. Financial support for medical writing assistance from Ada Ao-Baslock, PhD, of Powered 4 Significance LLC was provided by Teva Branded Pharmaceutical Products R&D.

The camshaft and crankshaft work in conjunction with each other. Both of these parts give the transmission the power it needs to run. These components are very intricate and operate on a timed sequence which changes depending on an automobile’s make and model. The camshaft and the crankshaft have sensors attached to them that help determine the order at which these valves open and close.

Results from both univariate and logistic regression analyses showed that patients who achieved MCyR to their most recent TKI (before progression) may more likely achieve MCyR with omacetaxine. This is similar to other models in which response to first-line imatinib was a predictor of CCyR to subsequent dasatinib or nilotinib.4, 5 Taken together, these results are particularly interesting in that the previous response to initial TKI treatment may predict a subsequent response whether the secondary treatment is a TKI or not. In this trial, 9% of patients without MCyR and 41% of those with MCyR to prior TKI achieved MCyR with omacetaxine (Table 1). The finding that patients without CHR at baseline despite the use of HU were least likely to achieve MCyR with omacetaxine (in univariate analysis) may simply be owing to the presence of more proliferative disease in this patient subset. Importantly, response to omacetaxine is not dependent on BCR-ABL1 mutation status (T315I or other mutations), as would be expected since the activity of omacetaxine is independent of direct BCR-ABL1 binding.6 This contrasts with treatment with second-generation TKIs, in which the absence of specific, more sensitive baseline mutations was associated with longer PFS.7 Preliminary post hoc analyses in patients with CML-CP treated with ponatinib also noted that presence of T315I was not a significant prognostic factor for response.8

No one should ignore warning signs that their camshaft sensor is broken. This part is crucial to an automobile’s performance, and this article has shown what happens when it’s damaged. Anyone in need of a replacement camshaft sensor should contact ATL Diesel immediately. We sell high-quality Volvo diesel engine parts for a decent price. Our remanufactured parts have been brought back to life and are extremely reliable. We understand how much engine issues disrupt a trucking company’s workflow. Every minute a driver is stuck on the side of the road due to a faulty part, a corporation loses money. So, it’s our mission as a team to help customers through every step of the repair process. We’ll help drivers and their supervisors determine what parts are right for their vehicle so that they can get back on the road as quickly as possible.

Mcyrrowing club

To identify patients with prior TKI resistance or intolerance most likely to benefit from a non-TKI treatment, we evaluated the association between baseline characteristics and achievement of MCyR in post hoc analysis of data from all 76 CML-CP patients included in the pivotal efficacy analysis of omacetaxine.1, 2 We also examined the association of response with survival via retrospective landmark analyses. The final data cutoff for this analysis was 12 October 2012. Eighteen baseline variables were examined for association with the achievement of MCyR using both univariate analysis (that is, Fisher's exact test) and multivariate analysis (that is, logistic regression; Table 1). Four of 18 baseline variables evaluated in univariate analysis were associated with the increased likelihood of achieving MCyR with omacetaxine at a significance level of P⩽0.1; these included achievement of complete hematologic response (CHR) with the most recent TKI; achievement of MCyR with the most recent TKI; no hydroxyurea (HU) use at baseline; and presence of CHR at baseline. The number of prior TKIs was not associated with achievement of MCyR. Among patients with resistance to two or more prior TKIs at baseline, 13 (19%) achieved MCyR with omacetaxine treatment (including seven CCyR and six partial CyR). Two of seven patients (29%) with intolerance to two or more TKIs at baseline achieved MCyR. Mutational status of BCR-ABL1 was also not predictive of response. Additional univariate analyses of MCyR rates by baseline CHR status and HU use showed the highest response rate (5/13 patients, 39%) in patients who were in CHR at baseline without the use of HU, and the lowest rate in patients who were not in CHR at baseline despite the use of HU (2/33 patients, 6%); MCyR rate was 25% (2/8) in patients having CHR at baseline with HU use and 23% (5/22) in patients without CHR and without HU use at baseline.

Interpretation of these results is limited by the small cohort, single-arm design and the exploratory, post hoc nature of these analyses. However, this information may help inform treatment decisions when considering a non-TKI approach in CML-CP patients.

Abbreviations: BSA, body surface area; CHR, complete hematologic response; CI, confidence interval; CML, chronic myeloid leukemia; HU, hydroxyurea; MCyR, major cytogenetic response; OR, odds ratio; TKI, tyrosine kinase inhibitor.

We also examined the association of response with survival using retrospective landmark analyses to estimate the median OS from time of omacetaxine initiation in patients with/without CHR at 3 months and with/without CyR or MCyR at 3, 6 and 12 months who remained on treatment at the specified time points. Of 76 CML-CP patients treated, 53 (70%) remained on treatment at 3 months, 43 (57%) at 6 months and 25 (33%) at 12 months. The 47 patients who achieved or maintained CHR by 3 months demonstrated a longer median OS than the 6 patients without CHR (49.5 vs 15.0 months; Table 2); median OS was not reached among the 17 patients with CHR at baseline who maintained response at 3 months (95% CI 17.8 months–not reached) and was 40.3 months (95% CI 22.9–59.4 months) in the 30 patients without CHR at baseline who achieved CHR with omacetaxine. A correlation between MCyR at 3 months and 6 months (n=8 each) and median OS was not reached (all P>0.5), possibly because of the small size of the cohort. For the 6 patients achieving MCyR by 12 months, median OS was not reached and all 6 patients achieved CCyR (five patients were alive with a median follow-up of 48.7 months (range 43.2–57.2 months)), compared with a median OS of 59.4 months in the 19 patients without MCyR at 12 months (P=0.3375).

Meir Wetzler reported personal fees from Teva, Ariad and Boehringer Ingelheim, and grants from Bristol–Myers Squibb during the conduct of the study. Hagop M Kantarjian reports research grants from Teva during the conduct of the study. Michele Baccarani reports personal fees from Ariad, Bristol–Myers Squibb, Pfizer and Novartis during the conduct of the study. Franck E Nicolini reports grants, personal fees and non-financial support from Novartis Pharma, personal fees from Bristol–Myers Squibb and personal fees from Ariad during the conduct of the study. Luke Akard reports grants and personal fees from Teva, Ariad and Novartis, personal fees from Bristol–Myers Squibb and grants from Pfizer outside the conduct of the study. Elizabeth Li is employed by PharmaStat LLC, and reports payment for statistical analysis from Teva during the conduct of the study. Mihaela Munteanu reports employment by Teva during the conduct of the study. Jorge Cortes reports grants from Teva during the conduct of the study, and grants and personal fees from Ariad, Bristol–Myers Squibb, Novartis and Pfizer outside the submitted work. The remaining authors declare no conflict of interest.

Abbreviations: CHR, complete hematologic response; CI, confidence interval; CML-CP, chronic-phase chronic myeloid leukemia; CyR, cytogenetic response; MCyR, major cytogenetic response; mo, months; NR, not reached; OS, overall survival.

Camshaft and crankshaft sensors tell a car’s computer when conditions are ideal for an engine to start. For example, the camshaft sensor will not allow the valves to open if there’s an inadequate amount of fuel or air in the mixture. The transmission needs the mixture to be the perfect combination of air and fuel to run smoothly. That’s why camshaft sensors are so important to diesel engine efficiency. If the sensor sends an inaccurate reading to the computer and the valves open before they should, the air-fuel mixture that’s needed to start an engine will be imbalanced. The rest of this article will discuss why that is an issue and what warning signs drivers should look out for.